Lynne Glaser
Nurse Practitioner · Cumberland, RINPI 1275520694
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.4% of the total across 827 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 57 manufacturers, the largest accounting for just 10.5% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2024 at $4,202 and has fallen 59.2% since, to $1,716 in 2025. Among nurse practitioner clinicians in RI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 827 payments — averaging $20.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- AstraZeneca$2K
- Amgen$1K
- Teva Pharmaceuticals USA, Inc.$1K
- Pfizer$1K
- Otsuka America Pharmaceutical, Inc.$955
- plus $9K from 51 others
What the payments were for
- Food & beverage$17,03999%
- Education$971%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$17,137 in reported general payments places this provider in the 95th percentile of 396 nurse practitioner providers in Rhode Island.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 97 | $109,943 |
| AustedoDeutetrabenazine | 13 | $98,252 |
| MounjaroTirzepatide | 62 | $65,307 |
| XifaxanRifaximin | 13 | $42,696 |
| EliquisApixaban | 77 | $38,181 |
| JardianceEmpagliflozin | 63 | $36,906 |
| TrulicityDulaglutide | 27 | $27,725 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 35 | $24,494 |
| FarxigaDapagliflozin Propanediol | 38 | $24,177 |
| MyrbetriqMirabegron | 23 | $14,242 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 13 | $14,186 |
| GemtesaVibegron | 41 | $13,667 |
| TradjentaLinagliptin | 26 | $13,206 |
| XareltoRivaroxaban | 11 | $11,961 |
| OxycontinOxycodone Hcl | 13 | $11,893 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $276 | $109,94397 claims |
| Teva Pharmaceuticals USA, Inc.Austedo | $1,131 | $98,25213 claims |
| Lilly USA, LLCMounjaro, Trulicity | $365 | $93,03289 claims |
| Boehringer IngelheimJardiance, Tradjenta | $467 | $50,11289 claims |
| AstraZenecaBreztri Aerosphere, Farxiga | $1,593 | $48,67173 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan | $196 | $42,69613 claims |
| PfizerEliquis | $1,076 | $38,18177 claims |
| Astellas Pharma US IncMyrbetriq | $249 | $14,24223 claims |
| GSKTrelegy Ellipta | $309 | $14,18613 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $84 | $13,66741 claims |
| Johnson & JohnsonXarelto | $494 | $11,96111 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Vyvanse | $139 | $8,00822 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 396 nurse practitioner providers in Rhode Island.
Other nurse practitioner in Cumberland
- Jenna BoutilierCumberland$676
- Megan GerntCumberland$366
- Linda YoungLincoln$19K
- Stephanie CostaWarwick$9K
- Maria SilvaJohnston$7K
- Natalie DriscollMiddletown$6K
- Lea KellyProvidence$5K
- Kathleen ParkerWarwick$5K
- Priscilla PonteEast Providence$5K
- Jennifer JohnsonNarragansett$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.